• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Arterial thrombotic events and acute coronary syndromes with cancer drugs: Are growth factors the missed link? What both cardiologist and oncologist should know about novel angiogenesis inhibitors
Abstract: We aimed to revise the increasingly accruing data about the association between anti-tyrosinkinase, “targeted” cancer drugs and the development of arterial thrombotic events or acute coronary syndromes. Further insights into the involved pathophysiologic mechanisms, and into the clinical implications are overviewed.Antiangiogenesis has become a mainstream of cancer therapy, leading to development of a specific class of drugs. Besides, a “wider” angiogenesis network made up of several growth factors, can be recognized as target of a higher number of compounds. Their widespread use has been progressively fa...
Source: International Journal of Cardiology - February 14, 2013 Category: Cardiology Authors: Elena Conti, Adriana Romiti, Maria Beatrice Musumeci, Jasmine Passerini, Luigi Zezza, Vittoria Mastromarino, Chiara D'Antonio, Paolo Marchetti, Francesco Paneni, Camillo Autore, Massimo Volpe Tags: Reviews Source Type: research

The tell-tale heart: molecular and cellular responses to childhood anthracycline exposure
Since the modern era of cancer chemotherapy that began in the mid-1940s, survival rates for children afflicted with cancer have steadily improved from 10% to current rates that approach 80% (60). Unfortunately, many long-term survivors of pediatric cancer develop chemotherapy-related health effects; 25% are afflicted with a severe or life-threatening medical condition, with cardiovascular disease being a primary risk (96). Childhood cancer survivors have markedly elevated incidences of stroke, congestive heart failure (CHF), coronary artery disease, and valvular disease (96). Their cardiac mortality is 8.2 times higher tha...
Source: AJP: Heart and Circulatory Physiology - November 15, 2014 Category: Cardiology Authors: Lindsey, M. L., Lange, R. A., Parsons, H., Andrews, T., Aune, G. J. Tags: REVIEW Source Type: research

Subclinical Myocardial Impairment Occurred in Septal and Anterior LV Wall Segments After Anthracycline-Embedded Chemotherapy and did not Worsen During Adjuvant Trastuzumab Treatment in Breast Cancer Patients.
Abstract In a previous study of breast cancer patients, we found changes in cardiac function and size during the early stages of adjuvant trastuzumab (Herceptin(®)) therapy. Here we present a subgroup analysis of this patient cohort. This subgroup received a anthracycline-embedded chemotherapy followed by at least 3 months up to 6 months of adjuvant Herceptin(®) therapy. Twenty-seven female breast cancer patients with Her-2/-neu overexpression were studied using conventional echocardiography and 2D speckle tracking. These methods were done before anthracycline-embedded chemotherapy, before adjuvant trastuzumab...
Source: Cardiovascular Toxicology - May 29, 2015 Category: Cardiology Authors: Lange SA, Jung J, Jaeck A, Hitschold T, Ebner B Tags: Cardiovasc Toxicol Source Type: research

Cancer-related multiple brain infarctions caused by Trousseau syndrome in a patient with metastatic colon cancer: a case report.
Abstract Thromboembolism that occurs in association with a malignant tumor is known as Trousseau syndrome. We herein present a case of Trousseau syndrome during systemic chemotherapy for metastatic colon cancer. A 65-year-old man with multiple liver metastases underwent primary tumor resection and systemic chemotherapy. Multiple brain infarctions were detected by magnetic resonance imaging immediately after first-line chemotherapy, which was deemed ineffective. There was no evidence of cardioembolic stroke or carotid atherosclerosis. Although the patient was initially asymptomatic, he subsequently developed paraly...
Source: Atherosclerosis - September 8, 2016 Category: Cardiology Authors: Akiyama T, Miyamoto Y, Sakamoto Y, Tokunaga R, Kosumi K, Shigaki H, Kurashige J, Iwatsuki M, Baba Y, Yoshida N, Baba H Tags: Surg Case Rep Source Type: research

Predictors of venous thromboembolism recurrence and the bleeding events identified using a Japanese healthcare database.
CONCLUSIONS: These findings obtained from healthcare database suggest predictors either for recurrent VTE and bleeding that should be considered when selecting treatment to reduce the risk of recurrent VTE and mitigate bleeding. PMID: 28245956 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - February 24, 2017 Category: Cardiology Authors: Nakamura M, Yamada N, Oda E, Matsubayashi D, Ota K, Kobayashi M, Matsushita Y, Kaburagi J, Ibusuki K, Takita A, Iwashita M, Yamaguchi T Tags: J Cardiol Source Type: research

Vitamin C: historical perspectives and heart failure
AbstractVitamin C (Vit C) is an ideal antioxidant as it is easily available, water soluble, very potent, least toxic, regenerates other antioxidants particularly Vit E, and acts as a cofactor for different enzymes. It has received much attention due to its ability in limiting reactive oxygen species, oxidative stress, and nitrosative stress, as well as it helps to maintain some of the normal metabolic functions of the cell. However, over 140 clinical trials using Vit C in different pathological conditions such as myocardial infarction, gastritis, diabetes, hypertension, stroke, and cancer have yielded inconsistent results....
Source: Heart Failure Reviews - October 8, 2020 Category: Cardiology Source Type: research

Adverse Cerebral Cardiovascular Events Associated With Checkpoint Kinase 1 Inhibitors: A Systemic Review
Abstract: Checkpoint kinase 1 (CHK1) plays a broad role in regulating the cell cycle process and is involved in the pathogenesis of various malignant tumors. Preclinical and animal studies have shown that CHK1 inhibitors can enhance the cytotoxic effects of radiotherapy and chemotherapy. Currently, CHK1 inhibitors are actively tested in clinical trials. Nonspecific adverse cerebral cardiovascular events were reported after CHK1 inhibitor use; these events need to be monitored and managed carefully during the clinical application of CHK1 inhibitors. To get a better understanding of these, noteworthy adverse cardiovascul...
Source: Journal of Cardiovascular Pharmacology - May 1, 2021 Category: Cardiology Tags: Review Article Source Type: research

Advancements of Prussian blue-based nanoplatforms in biomedical fields: Progress and perspectives
J Control Release. 2022 Oct 7:S0168-3659(22)00677-0. doi: 10.1016/j.jconrel.2022.10.007. Online ahead of print.ABSTRACTPrussian blue (PB) nanoparticles possess excellent physicochemical properties, including imaging features, robust photothermal conversion ability, catalytic activity, surface modifiability, effective drug loading, good stability, biocompatibility and biodegradability. With the advancement of nanotechnology, diverse PB-based nanoplatforms have been developed for biomedical applications. This review systematically summarized recent studies on PB-based nanoplatforms in the treatment of tumor (photothermal the...
Source: Atherosclerosis - October 10, 2022 Category: Cardiology Authors: Yanhui Wang Zonghao Liang Ziyang Liang Wenfeng Lv Min Chen Yi Zhao Source Type: research

Chemotherapy-Induced Arrhythmias
Abstract: Cardio-oncology is a subspeciality within cardiology that has developed primarily as a consequence of the cardiovascular implications of cancer and its therapeutics. Arrhythmias are increasingly recognized as an adverse feature of many chemotherapeutic agents. This relationship is poorly defined and studied in the literature compared with other side effects of chemotherapy. In this review, we appraise the published literature on arrhythmogenic consequences of chemotherapeutic agents and summarize the available evidence. Atrial fibrillation (AF) and other supraventricular tachycardias are frequently observed i...
Source: Journal of Cardiovascular Pharmacology - October 1, 2022 Category: Cardiology Tags: Invited Review Article Source Type: research

Exercise for the Prevention of Anthracycline-induced Functional Disability and Cardiac Dysfunction: The BReast Cancer Randomized EXercise InTervention (BREXIT) Study
Conclusions: In women with early-stage BC undergoing AC, 12-months of ExT did not attenuate functional disability but provided large and clinically meaningful benefits on VO2peak and cardiac reserve. Clinical Trial Registration: URL: https://www.anzctr.org.au/ Unique Identifier: ACTRN12617001408370.PMID:36342348 | DOI:10.1161/CIRCULATIONAHA.122.062814
Source: Circulation - November 7, 2022 Category: Cardiology Authors: Stephen J Foulkes Erin J Howden Mark J Haykowsky Yoland Antill Agus Salim Sophie S Nightingale Sherene Loi Piet Claus Kristel Janssens Amy M Mitchell Leah Wright Ben T Costello Anniina Lindqvist Lauren Burnham Imogen Wallace Robin M Daly Steve F Fraser An Source Type: research